Rational Pharmacotherapy in Cardiology

Advanced search

Treatment of Vasovagal Syncope Associated with Asystole: Literature Review and Case Report of Long-term Follow-up

Full Text:


Vasovagal syncope (VVS) can occur in every third of human population. Clinical symptoms of VVS areas a result of arterial hypotension with critical global cerebral hypoperfusion due to vasodilatation and bradicardia. Bradicardia is manifested as sinus node dysfunction and atrioventricular conduction disturbances due to activation of nervus vagus. Asystole can take place in some cases. Lack of efficacy of permanent pacemaker founds in patients to prevent of VVS. The results of double blind placebo controlled studies, European and American expert's opinions, probable causes of lack of efficacy of pacemakers in such category of patients and way of solution of this problem are discussed in the review. Syncope recurrences in spite of pacemaker implantation, risk of surgery complications and good life prognosis are arguments for therapeutic approach, now suitable for the most of patients with VVS. Case report (VVS with asystole but without of pacemaker implantation) with successful follow-up is analyzed in the article.

About the Authors

A. V. Pevzner
National Medical Research Center of Cardiology
Russian Federation

Alexander V. Pevzner - eLibrary SPIN 7029-3618


E. A. Kuchinskaya
National Medical Research Center of Cardiology
Russian Federation

Elena A. Kuchinskaya - eLibrary SPIN 4238-4483


V. G. Kiktev
National Medical Research Center of Cardiology
Russian Federation

Vacheslav G. Kiktev - eLibrary SPIN 4323-5347


G. I. Kheimets
National Medical Research Center of Cardiology
Russian Federation

Grigory I. Kheimets - eLibrary SPIN 8304-3060



1. . Shen W, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS Guideline for the evaluation and man-agement of patients with syncope. JACC. 2017;70(5):e39-e110. DOI:10.1016/j.jacc.2017.03.003.

2. Ganzeboom KS, Mairuhu G, Reitsma JB, et al. Lifetime cumulative incidence of syncope in the general population: a study of 549 Dutch subjects aged 35-60 years. J Cardiovasc Electrophysiol. 2006;17(11):1172-76. DOI:10.1111/j.1540-8167.2006.00595.x.

3. Chen LY, Shen WK, Mahoney DW, et al. Prevalence of syncope in a population aged more than 45 years.Am. J. Med. 2006;119(12):1088.e1-7. DOI:10.1016/j.amjmed.2006.01.029.

4. Kenny R.A., Brignole M., Dan G.A., et al. Syncope Unit: rationale and requirement-the European Heart Rhythm Association position statementendorsed by the Heart Rhythm Society. Europace. 2015;17:1325-40. DOI:10.1093/europace/euv115.

5. Pevzner AV, Kuchinskaya EA. Vasovagal syncope. In.: Chazov E.I., Golitsyn S.P., eds. Cardiac arrhythmias guide. Moscow: GEOTAR Media; 2008: 223-244 (In Russ.) ISBN: 978-5-9704-1643-3.

6. Brignole M, Menozzi C, Del Rosso A, et al. New classification of haemodynamics of vasovagal syncope: beyond the VASIS classification. Europace. 2000;2:66-76. DOI:10.1053/eupc.1999.0064.

7. Brignole M, Moya A, de Lange F, et al. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J. 2018;39:1-69. DOI:10.1093/eurheartj/ehy037.

8. Benditt DG, Ferguson DW, Grub BP, et al. Tilt table testing for assessing syncope. American college of cardiology. J Am Coll Cardiol. 1996;28:263-75. DOI:10.1016/0735-1097(96)00236-7.

9. Pevzner AV, Kuchinskaya EA, Vershuta EV, et al. Long-term orthostatic and bicycle exercise tests in differential diagnosis of syncopal conditions of unclear origin. Ter Arkhiv. 2004;11:23-7 (In Russ.)

10. Krahn A, Klein G, Yee R, et al. Randomized Assessment of Syncope Trial. Conventional Diagnostic Testing Versus a Prolonged Monitoring Strategy. Circulation. 2001;104:46. DOI:10.1161/01.cir.104.1.46.

11. Farwell D, Freemantle N, Sulke A. Use of implantable loop recorders in the diagnosis and management of syncope. Eur Heart J. 2004;25(14):1257-63. DOI:10.1016/j.ehj.2004.03.010.

12. Brignole M, Vardas P, Hoffman E, et al. Indications for the use of diagnostic implantable and external ECG loop recorders. Europace. 2009;11:671-87. DOI:10.1093/europace/eup097.

13. Moya A, Brignole M, Menozzi C, et al. on behalf of the International Study on Syncope ofUncertain Etiology (ISSUE) Investigators. Mechanism of syncope in patients with isolated syncope and in patients with tilt positive syncope. Circulation. 2001;104:1261-67. DOI:10.1161/hc3601.095708.

14. Van Dijk N, Quartieri F, Blanc JJ, et al. Effectiveness of physical counterpressure maneuvers in preventing vasovagal syncope: the physical counterpressure maneuvers trial (PC-trial). J Am Coll Cardiol. 2006;48:1652-57. DOI:10.1016/j.jacc.2006.06.059.

15. Kuchinskaya EA, Pevzner AV. Lifestyle Modification as a Method of Treatment of Vasovagal Syncope. Kardiologiia. 2020;60(1):93-8 (In Russ.) DOI 10.18087/cardio.2020.1.n776.

16. Brignole M, Menozzi C, Bottoni N, et al. Mechanisms of syncope caused by transient bradycardia and the diagnostic value of electrophysiologic testing and cardiovascular reflexivity maneuvers. Am J Cardiol. 1995;76(4):273-8. DOI:10.1016/s0002-9149(99)80080-0.

17. Lacroix D, Kouakam C, Klug D, et al. Asystolic cardiac arrest during Head-Up Tilt Test: incidence and therapeutic implications. Pacing Clin Electrophysiol. 1997;20:2746-54. DOI:10.1111/j.1540-8159.1997.tb05432.x.

18. Baron-Esquivias G, Pedrote A, Cayuela A, et al. Long-term outcome of patients with asystole induced by head-up tilt test. Eur. Heart J. 2002;23:483-89. DOI:10.1053/euhj.2001.2900.

19. Vershuta EV, Pevzner AV, Ermishkin VV, et al. Spectral indices of heart rate variability in patients with vasovagal syncopes according to evidence of 5-min ECG. Ter Arkhiv. 2009;4:17-21 (In Russ)

20. Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace. 2013;15(8):1070-18. DOI:10.1093/europace/eut206.

21. Revishvili ASh, Shlyahto EV, Popov SV, et al. Clinical recommendations for electrophysiological studies, catheter ablation and the use of implantable antiarrhythmic devices (2017) [cited by Jan 02, 2020]. Available from: (In Russ.)

22. Varosy PD, Chen LY, Miller AL, et al. Pacing as a Treatment for Reflex-Mediated (Vasovagal, Situational, or Carotid Sinus Hypersensitivity) Syncope: A Systematic Review for the 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope. J Am Coll Cardiol. 2017;70:664-79. DOI:10.1016/j.jacc.2017.03.004.

23. Conolly S, Sheldon R, Thorpe K, et al. Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope (VPS II): a randomized trial. JAMA. 2003;289(17):2224-29. DOI:10.1001/jama.289.17.2224.

24. Raviele A, Giada F, Menozzi C, et al. A randomized, double-blind, placebo-controlled study of permanent cardiac pacing for the treatment of recurrent tilt-induced vasovagal syncope. The vasovagal syncope and pacing trial (SYNPACE). Eur Heart J. 2004;25(19):1741-48. DOI:10.1016/j.ehj.2004.06.031.

25. Brignole M, Menozzi C, Moya A, et al. Pacemaker therapy in patients with neurally-mediated syncope and documented asystole. Third international study on syncope of unknown etiology (IS- SUE-3): a randomized trial. Circulation. 2012;125(21):2566-71. DOI:10.1161/CIRCULATIONA-HA.111.082313.

26. Ryan D, Nick S, Colette S, et al. Carotid sinus syndrome, should we pace? A multicentre, randomised control trial (Safepace 2). Heart. 2010;96(5):347-51. DOI:10.1136/hrt.2009.176206.

27. Brignole M, Donateo P, Tomaino M, et al. Benefit of pacemaker therapy in patients with presumed neurally mediated syncope and documented asystole is greater when tilt test is negative an analysis from the third international study on syncope of uncertain etiology (ISSUE-3).Circ Arrhythm Elec-trophysiol. 2014;7:10-16. DOI:10.1161/CIRCEP.113.001103.

28. Kheymets GI, Pevzner AV, Pogoza AN, Golitsin CP. A five-minute tilt table test as part of diagnostic algorithm of syncope. Kardiologicheskii Vestnik. 2017;12(3):70-4 (In Russ.)

29. Occhetta E, Bortnik A, Audoglio R, et al. Closed loop stimulation in patients of vasovagal syncope. Inotropy controlled pacing in vasovagal syncope (INVASY): a multicentre randomized, single blind, controlled study. Europace. 2004 6:538-47. DOI:10.1016/j.eupc.2004.08.009.

30. Rattanawong P, Riangwiwat T, Chongsathidkiet P, et al. Closed-looped stimulation cardiac pacing for recurrentvasovagal syncope: A systematic review and meta-analysis.J Arrhythm. 2018;34(5):556- 64. DOI:10.1002/joa3.12102.

31. Brignole M, Tomaino M, Aerts A, et al. Benefit of dual-chamber pacing with Closed Loop Stimulation in tilt-induced cardio-inhibitory reflex syncope (BIOSync trial): study protocol for a randomized controlled trial. Trials. 2017;18(1):208. DOI:10.1186/s13063-017-1941-4.

32. Brignole M, Ammirati F, Arabia F, et al. Assessment of a standardized algorithmfor cardiac pacing in older patients affected by severe unpredictable reflex syncopes. Eur Heart J. 2015;36(24):1529-35. DOI:10.1093/eurheartj/ehv069.

33. Soteriades E.S., Evans J.C., Larson M.G., et al. Incidence and prognosis of syncope. N Engl J Med. 2002;347(12):878-85. DOI:10.1056/NEJMoa012407.

34. Pevzner AV, Kuchinskaya EA, Albitskaya KV, et al. Efficacy of compression therapy of the lower limbs in the treatment of patients with vasovagal syncopes. Ter Arkhiv. 2007;79(1):52-5 (In Russ.)

35. Sheldon R, Raj S, Rose S, et al. Fludrocortisone for the prevention of vasovagal syncope.A randomized, placebo-controlled trial. J Am Col Cardil. 2016;68(1):1-9. DOI:10.1016/j.jacc.2016.04.030.

36. Kaufmann H, Saadia D, Voustianiouk A. Midodrine in neurally mediated syncope: a double-blind, randomized crossover study. Ann Neurol. 2002;52(3):342-45. DOI:10.1002/ana.10293.

37. Ward CR, Gray IC, Gilroy JJ, Kenny PA. Midodrine: a role in the treatment of neurocardiogenic syncope. Heart. 1998;79(1):45-9. DOI:10.1136/hrt.79.1.45.

38. Romme J, van Dijk N, Go-Schon I, et al. Effectiveness of midodrine treatment in patients with recur- rentvasovagal syncope not responding to non-pharmacological treatment (STAND-trial). Europace. 2011;13(11):1639-47. DOI:10.1093/europace/eur200.

39. Kuchinskaya EA, Pevzner AV, Vershuta EV, et al. Results of midodrin treatment of vasovagal syncope. Ter Arkhiv. 2004;76(8):38-41 (In Russ.)

40. Pevzner AV, Kuchinskaya EA, Vershuta EV, et al. Successful midodrin treatment for vasovagal syncopes accompanied by asystole. Klinicheskaya Medicina. 2004;82(9):53-6 (In Russ.)

41. Sheldon R, Lei L, Guzman J, Kus T. A proof of principle study of atomoxetine for the prevention of vasovagal syncope: the prevention of syncope trial VI. Europace. 2019;21:1733-41. DOI:10.1093/eu-ropace/euz250.


For citations:

Pevzner A.V., Kuchinskaya E.A., Kiktev V.G., Kheimets G.I. Treatment of Vasovagal Syncope Associated with Asystole: Literature Review and Case Report of Long-term Follow-up. Rational Pharmacotherapy in Cardiology. 2021;17(2):315-322. (In Russ.)

Views: 281

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)